December 16, 2009 08:30 ET

ONE Bio Creates Advisory Board; Appoints Dr. Jian Ming Chan of the Department of Environmental Science & Engineering at Fudan University as Chairman

MIAMI, FL--(Marketwire - December 16, 2009) - ONE Bio, Corp. ("ONE" or the "Company") (OTCBB: ONBI), an innovative company utilizing green process manufacturing to produce raw chemicals and herbal extracts, natural and health supplements and organic products, announced today that accomplished Asian researcher, Dr. Jian Ming Chan, ONE's Chief Scientist, has been appointed Chairman of the newly formed ONE Bio Advisory Board.

Dr. Chan will work with the Company's board of directors to (a) locate & select respected members of the bio-science community for the Company's Advisory Board, (b) advise and educate ONE's board of directors on developments and research relating to natural supplements, herbal and chemical extracts and organic products and (c) provide strategic recommendations to ONE Bio regarding potential impact or benefits any new developments may have on the Company's product portfolio.

Dr. Chan earned his doctorate degree from Fudan University in 1993. Dr. Chan is the current Chair of the Department of Environmental Science & Engineering at Fudan University. Over the past 15 years Dr. Chan has held various senior teaching and management positions in several universities, including Japan's Tokyo and Osaka Universities. During his tenure at Fudan University in China, Dr. Chan's positions have ranged from senior Research partner to Dean of Chemistry Faculty. Dr. Chan has devoted his career to natural science, environmental science, and bio-engineering. His life's ambition is to promote human health by improving the environment. In 1999, Dr. Chan was named the Distinguished Youth Professor of Shanghai. Over the last decade Dr. Chan has received several honours and awards from various committees, universities and the government of China for his research accomplishments.

"I'm very pleased Dr. Chan has accepted our nomination as Chairman of our newly created advisory board. Dr. Chan has made significant contributions to our research team since joining the Company. Some of our key patents are as a result of his creations and work. We believe his research experience and relationships will be instrumental as we continue to focus on ONE Bio's growth," commented Company CEO, Marius Silvasan. "We count on Dr. Chan to surround himself with top researchers in Asia and aboard in the fields of natural supplements, herbal and chemical extracts and organic products," added Silvasan.

About ONE Bio, Corp.

ONE Bio, Corp. ("ONE") (OTCBB: ONBI) ( headquartered in Miami, FL, is an innovative company utilizing green process manufacturing to produce raw chemicals and herbal extracts, natural supplements and organic products. ONE is focused on the Asia Pacific region. Key products include widely recognized Solanesol, CoQ10, Resveratrol and 5-HTP, organic fertilizers, and organic bamboo health food and beverages. ONE's growth plan targets an aggressive acquisition driven strategy supported by strong organic growth. Through ONE, small private companies gain access to capital, experienced management and strategic insight. ONE builds strong synergies amongst all subsidiaries to enhance shareholder value. ONE is working with each subsidiary to promote organic and acquisition driven growth.

This press release includes statements that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Reform Act"). ONE Bio, Corp. claims the protection of the safe-harbor for forward-looking statements contained in the Reform Act. These forward-looking statements are often characterized by the terms "may," "believes," "projects," "expects," or "anticipates," and do not reflect historical facts. Specific forward-looking statements contained in this press release include, but are not limited to: our successful integration of diversified growth companies, impact of the company's expansion plan, and new business development success, future financial results, development and acquisition of new product lines and services, the impact of competitive products or pricing from technological changes, the effect of economic conditions and other uncertainties. The forward-looking statements contained herein involve risks and uncertainties that could cause actual results to differ materially from the expectations contained in any such forward-looking statements. These risks include, but are not limited to: failure to manage operating expenses or integrate new companies and/or technologies, each of which could have a material impact on our business, our financial results, and the company's stock price. These risks and other factors are detailed in the Company's regular filings with the U.S. Securities and Exchange Commission. Most of these factors are difficult to predict accurately and are generally beyond the Company's control. Forward-looking statements speak only as to the date they are made and ONE Bio, Corp. does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.

Contact Information